| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17530050902893311 |
| P698 | PubMed publication ID | 23485205 |
| P50 | author | Pierluigi Toniutto | Q56921390 |
| Carlo Fabris | Q117805135 | ||
| Mario Pirisi | Q53754880 | ||
| P2093 | author name string | Rosalba Minisini | |
| P2860 | cites work | Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C. | Q54575534 |
| Role of CYP2D6 polymorphism in predicting liver fibrosis progression rate in Caucasian patients with chronic hepatitis C. | Q54610700 | ||
| Association of functional gene polymorphisms of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-9 with the progression of chronic liver disease. | Q54659038 | ||
| Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. | Q54674968 | ||
| Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms | Q57611892 | ||
| A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection | Q58098412 | ||
| The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection | Q58099055 | ||
| Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions | Q58325022 | ||
| Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research | Q22010973 | ||
| Epoxide hydrolases: biochemistry and molecular biology | Q24290733 | ||
| Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein | Q24319002 | ||
| p68 RNA helicase is an essential human splicing factor that acts at the U1 snRNA-5' splice site duplex | Q24537595 | ||
| The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games | Q24683018 | ||
| Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection | Q27472839 | ||
| A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C | Q27477866 | ||
| Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study | Q27477962 | ||
| The CCR5- 32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source | Q27477986 | ||
| Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor | Q27485871 | ||
| Human leukocyte antigen class II associations with hepatitis C virus clearance and virus‐specific CD4 T cell response among Caucasians and African Americans | Q27489728 | ||
| Clinical importance of the cytochromes P450 | Q28208454 | ||
| Toll-like receptors as adjuvant receptors | Q28209227 | ||
| Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets | Q28303698 | ||
| The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C | Q28344953 | ||
| Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups | Q29614459 | ||
| SLCO1B1 variants and statin-induced myopathy--a genomewide study | Q29619028 | ||
| Structure and function of matrix metalloproteinases and TIMPs | Q30014818 | ||
| A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease | Q33972858 | ||
| How to interpret a genome-wide association study | Q34010528 | ||
| Methylenetetrahydrofolate reductase: a common human polymorphism and its biochemical implications | Q34122151 | ||
| Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. | Q34525413 | ||
| Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection | Q34700869 | ||
| Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection | Q35010511 | ||
| Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal | Q35071658 | ||
| Genetic associations: false or true? | Q35119636 | ||
| Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy? | Q35161573 | ||
| Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease | Q35363566 | ||
| Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection | Q35595865 | ||
| Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy | Q35785037 | ||
| The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. | Q36564604 | ||
| IL-12p40: an inherently agonistic cytokine | Q36663486 | ||
| Regulation of matrix metalloproteinase gene expression | Q36682744 | ||
| Genomics of liver fibrosis and cirrhosis | Q36733946 | ||
| Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism | Q36913187 | ||
| Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer | Q37051422 | ||
| Hepatitis C virus infection: molecular pathways to metabolic syndrome | Q37151026 | ||
| Novel aspects of the renin-angiotensin-aldosterone-system | Q37175444 | ||
| Viral infection and iron metabolism | Q37191011 | ||
| Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy. | Q37225844 | ||
| Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis | Q37265953 | ||
| The natural history of recurrent hepatitis C and what influences this | Q37282591 | ||
| The role of interferon gamma in regulation of CD4+ T-cells and its clinical implications. | Q37291789 | ||
| A robust statistical method for case-control association testing with copy number variation | Q37443927 | ||
| Single nucleotide polymorphisms in the interferon-gamma and interleukin-10 genes do not influence chronic hepatitis C severity or T-cell reactivity to hepatitis C virus | Q40517945 | ||
| Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection | Q41604038 | ||
| A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection | Q41604084 | ||
| Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype. | Q42980668 | ||
| IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection | Q42982169 | ||
| Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation | Q42985774 | ||
| Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection | Q42993251 | ||
| Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin | Q42994306 | ||
| Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? | Q42997486 | ||
| Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations | Q42998202 | ||
| Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. | Q42999950 | ||
| Studies on TAQ1 polymorphism in the 3'untranslated region of IL-12P40 gene in HCV patients infected predominantly with genotype 3. | Q43000748 | ||
| Polymorphism of interferon-gamma gene at position +874 and clinical characteristics of chronic hepatitis C. | Q43030926 | ||
| Racial differences in HLA class II associations with hepatitis C virus outcomes | Q43032027 | ||
| Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection | Q43039746 | ||
| Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis | Q43042054 | ||
| Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. | Q43042142 | ||
| Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response | Q43049566 | ||
| Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection | Q43438665 | ||
| Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis | Q43614647 | ||
| Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. | Q43659671 | ||
| Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. | Q43755028 | ||
| HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis | Q43821840 | ||
| Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. | Q43867314 | ||
| Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease | Q44042294 | ||
| Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans | Q44042948 | ||
| Myeloperoxidase, a leukocyte-derived vascular NO oxidase | Q44044885 | ||
| Contribution of obesity to hepatitis C-related fibrosis progression | Q44162459 | ||
| Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. | Q44184034 | ||
| Analysis of the transforming growth factor-beta1 (TGF-beta1) codon 25 gene polymorphism by LightCycler-analysis in patients with chronic hepatitis C infection | Q44641347 | ||
| Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2(TAP2)*0201 Allele | Q44653924 | ||
| The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. | Q44898803 | ||
| The -2518 promotor polymorphism in the MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection | Q44965852 | ||
| Host genetic factors influence disease progression in chronic hepatitis C. | Q45191664 | ||
| Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection | Q45400167 | ||
| Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus | Q45403600 | ||
| Polymorphisms of the renin-angiotensin system and the severity of fibrosis in chronic hepatitis C virus infection | Q45424652 | ||
| Transforming growth factor-beta-1 genetic polymorphism in Japanese patients with chronic hepatitis C virus infection | Q45721793 | ||
| Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection | Q45722071 | ||
| A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection | Q45731096 | ||
| Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus | Q45731567 | ||
| Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection | Q45738602 | ||
| Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease | Q45750467 | ||
| A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. | Q45965385 | ||
| Differential effects of lipoprotein lipase on tumor necrosis factor-alpha and interferon-gamma-mediated gene expression in human endothelial cells | Q46418731 | ||
| Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients | Q46441212 | ||
| TNFalpha genotype affects TNFalpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. | Q46688143 | ||
| Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C. | Q46978228 | ||
| Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C. | Q47838763 | ||
| Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. | Q47993571 | ||
| No role of the -2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C. | Q50577777 | ||
| Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. | Q50584849 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | single-nucleotide polymorphism | Q501128 |
| P304 | page(s) | 355-370 | |
| P577 | publication date | 2009-05-12 | |
| P1433 | published in | Expert Opinion on Medical Diagnostics | Q5421210 |
| P1476 | title | Combinatorial use of single nucleotide polymorphisms to help predict liver fibrosis in patients with hepatitis C infections | |
| P478 | volume | 3 |
Search more.